| Identification | Back Directory | [Name]
AES-350 | [CAS]
847249-57-4 | [Synonyms]
AES-350
Histone deacetylases,AES 350,MV4-11,AES-350,Apoptosis,acute myeloid leukemia,AML,Inhibitor,inhibit,AES350,HDAC | [Molecular Formula]
C18H20N2O3 | [MDL Number]
MFCD34180323 | [MOL File]
847249-57-4.mol | [Molecular Weight]
312.36 |
| Chemical Properties | Back Directory | [density ]
1.218±0.06 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMF: 30 mg/ml,DMSO: 30 mg/ml,DMSO:PBS (pH 7.2) (1:3): 0.25 mg/ml,Ethanol: 1 mg/ml | [form ]
A crystalline solid | [pka]
8.93±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
AES-350 is a potent and orally active HDAC6 inhibitor with an IC50 and a Ki of 0.0244 μM and 0.035 μM, respectively. AES-350 is also against HDAC3, HDAC8 in an enzymatic activity assay with IC50 values of 0.187 μM and 0.245 μM, respectively. AES-350 triggers apoptosis in AML cells through HDAC inhibition and can be used for acute myeloid leukemia (AML) research[1]. | [in vivo]
AES-350 (oral gavage; 20 mg/kg; single dose) exhibits a relative good pharmacokinetic (PK) properties in CD-1 mice. The single dose oral bioavailability (F%) of 51 is 19.8%. In comparison, the reported F% for SAHA in mice is significantly lower (8%)[1]. | [IC 50]
HDAC6: 24.4 nM (IC50); HDAC3: 187 nM (IC50); HDAC11: 245 nM (IC50) | [storage]
4°C, protect from light | [References]
[1] Andrew E Shouksmith, et al. Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia. DOI:10.1021/acsmedchemlett.9b00471 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
InvivoChem
|
| Tel: |
13549236410 |
| Website: |
https://www.invivochem.cn/ |
|